Tempo Therapeutics
A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.
$14.5MFunding
ParticipantActivity from announced rounds
Gideon Strategic Partners is the investment organization named in RADAR and Tempo financing coverage.
RADAR combines RFID and computer vision for item-level retail inventory. Tempo develops injectable microporous scaffolds intended to support tissue regeneration. These records connect two distinct technical products to the same fully named investor.
A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.